Latest news

• Roche’s Xofluza issued FDA approval to treat influenza in children aged five years and older

  Roche has received approval from the US Food and Drug Administration (FDA) for a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil).

• Roche’s flu pill Xofluza gains EU approval

  The EC has authorised Xofluza (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged 12 years and above.

• Roche’s Xofluza pill wins FDA approval for post-exposure flu prevention

  Xofluza (baloxavir marboxil) is now indicated for use as a treatment to prevent influenza infection in people 12 years of age and above who have had contact with someone with influenza.

• Roche’s flu pill Xofluza moves closer towards EU approval

  The CHMP has recommended Xofluza (baloxavir marboxil) for approval in the EU as a treatment for uncomplicated influenza patients aged 12 years and above.

• Roche scores another FDA approval for Xofluza

  Expands use to patients at high risk of flu-related complications. Roche’s Xofluza (baloxavir marboxil) has received FDA approval for use in people who have a high risk of developing